Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : All About Sun Microsystems -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (39618)	12/22/2000 2:30:19 PM
From: High-Tech East	Read Replies (1) \| Respond to of 64865

* OFF TOPIC * OFF TOPIC * OFF TOPIC * ... for those of you who are interested, a big step forward *Abiomed Requests FDA Approval to Begin Human Trials of AbioCor Replacement Heart* BW HealthWire)--Dec. 22, 2000--Abiomed, leader in heart assist and replacement technology, announced today that it has completed its IDE submission to the U.S. Food and Drug Administration, requesting approval to commence initial human trials of its AbioCor Implantable Replacement Heart. "The completion of the AbioCor IDE submission is a major milestone on the path to bringing heart replacement technology to the tens of thousands of people in heart failure who have little hope of receiving a human heart transplant." said Dr. David Lederman, President and CEO. "This IDE submission is the culmination of years of development and testing. I want to acknowledge all the hard work and important contributions made by our team of dedicated employees and our clinical partners in achieving this important milestone." Dr. Lederman added. Dr. Robert Kung, Chief Scientific Officer explained, "Our testing of the AbioCor in preparation for initial human trials has been extensive and the results of this testing have been very encouraging. While we expect questions from the FDA as they review our IDE application, we believe that a thorough review of our submission should lead to the conclusion that the AbioCor is ready for initial human trials in select patient populations. Subject to regulatory approval, we hope for the first human implant of the AbioCor to occur in the U.S. during the first half of 2001. In the interim, we are working diligently to produce sufficient quantities of devices and interacting closely with members of our clinical centers to insure that we are all fully trained and ready." Abiomed's U.S. clinical centers are: Brigham and Women's Hospital teamed with Massachusetts General Hospital in Boston; Hahnemann University Hospital in Philadelphia; Jewish Heart and Lung Hospital in Louisville; Texas Heart Institute in Houston; and UCLA Medical Center in Los Angeles. The Company anticipates that international trials of the AbioCor will commence after the U.S. trials are underway. Dr. Kung added, "the proposed goals of the initial AbioCor human trials will be to demonstrate improved life expectancy with a reasonable quality of life for selected patients who are in end-stage heart failure and who are not candidates for heart transplantation or any other available therapy. Ultimately, the successful completion of clinical trials should generate the clinical data necessary to submit to the corresponding Regulatory Authorities for approval to market the AbioCor in the U.S. and internationally. We are very excited about this important step toward making this life-saving technology available for human use." An IDE, or Investigational Device Exemption, is an application that must be approved by the FDA prior to commencing human clinical trials with a new medical device. An IDE must be supported by significant data that describe the medical device's design, operational function and pre-clinical test results. An IDE also describes the nature, purpose and justification of the proposed clinical study. Based in Danvers, Massachusetts, ABIOMED is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's AbioCor implantable replacement heart is in an advanced stage of development and moving into a state of preparedness for initial human trials. ABIOMED currently manufactures and sells the BVS(R), a temporary heart assist device, for the support of all patients with failing but potentially recoverable hearts. Ken Wilson